Form 4: Aytu BioPharma Director Carl Dockery Acquires 1,500 Common Shares

Director Carl Dockery acquired 1,500 common shares of Aytu BioPharma, Inc. on November 6, 2024.

Summary

• Carl Dockery, a director of Aytu BioPharma, Inc., acquired 1,500 common shares on November 6, 2024.
• The shares were acquired at a price of $0.
• Following the transaction, Dockery directly owns 10,440 common shares.
• The filing indicates that the transaction was not made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The director's share acquisition could be interpreted slightly positively, but it's a small transaction.

Positives

• A director's acquisition of shares can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of shares by a director could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Aytu BioPharma, Carl Dockery, common shares, acquisition, Form 4, insider trading, beneficial ownership, director